|
US Biotechnology Firms Grew Exponentially in 2006
Year 2006 remained extraordinarily good for the US biotechnology
firms. The firms were able to deliver rapid growth in revenues and earn
huge profits. Biotechnology firms in US raised US$ 27.9 Billion in loans
and investments in this year, maximum since 2000. This reflected the
increasing alliances with drug makers of global industry.
advertisement
Financings, public offerings, and revenues all showed remarkable
increase as the biotechnology firms in US went on to strengthen their
position as innovation engines in pharmaceutical sector, as per Ernst &
Young - accounting & consulting firm - in their annual report card on
this industry.
Currently, there're 52 profitable biotechnology firms. A new genre of
firms is joining biotechnology giants, such as Genentech and Amgen, and
this has successfully propelled drugs through to the regulatory
approval, as per Gautam Jaggi, US based analyst for Ernst & Young Global
Health Sciences.
Above 4,000 biotechnology firms are into the business of manipulating
cells and genes. They are manipulated largely for developing drugs for
arthritis, cancer, and other diseases. Older makers of drug have paid to
formulate alliances with biotechs, after depending on chemistry for
developing products.
Globally, revenues from biotechnology exceeded US$ 70 Billion for the
1st time as Europe and Canada also enjoyed double digit growth. Venture
funding throughout the world reached a record US$ 5.4 Billion, also
total financing registered a growth of 42% to reach US $27.9 Billion.
Value of biotechnology market globally is expected to be US$ 226.1
Billion by the year 2010.
According to RNCOS report "US Biotech Market Analysis", "In 2005, total
revenues generated by the US biotechnolo gy market reached US$ 68.6
Billion, representing a CAGR of 15.16% (between 2001 and 2005). However
the industry is expected to generate US$ 131.8 Billion in revenues
towards the end of 2010."
This research report on "US Biotech Market Analysis" provides extensive
research and objective analysis of the Biotechnology industry in US.
This report helps clients in analyzing the opportunities critical to the
growth of The Biotechnology industry in US. Key issues addressed are:
major market trends in the US Biotechnology industry, opportunities and
challenges before the Biotechnology industry, etc.
About RNCOS E-Services Pvt Ltd.:
RNCOS, incorporated in the year 2002, is an industry research firm. It
has a team of industry experts who analyze data collected from credible
sources. They provide industry insights and analysis that helps
corporations to take timely and accurate business decision in today's
globally competitive environment.
For more information visit:
http://www.rncos.com/Report/IM0300.htm
Current Industry News: http://www.rncos.com/blog
Year 2006 remained extraordinarily good for the US biotechnology firms.
The firms were able to deliver rapid growth in revenues and earn huge
profits. Biotechnology firms in US raised US$ 27.9 Billion in loans and
investments in this year, maximum since 2000. This reflected the
increasing alliances with drug makers of global industry.
Financings, public offerings, and revenues all showed remarkable
increase as the biotechnology firms in US went on to strengthen their
position as innovation engines in pharmaceutical sector, as per Ernst &
Young - accounting & consulting firm - in their annual report card on
this industry.
Currently, there're 52 profitable biotechnology firms. A new genre of
firms is joining biotechnology giants, such as Genentech and Amgen, and
this has successfully propelled drugs through to the regulatory
approval, as per Gautam Jaggi, US based analyst for Ernst & Young Global
Health Sciences.
Above 4,000 biotechnology firms are into the business of manipulating
cells and genes. They are manipulated largely for developing drugs for
arthritis, cancer, and other diseases. Older makers of drug have paid to
formulate alliances with biotechs, after depending on chemistry for
developing products.
Globally, revenues from biotechnology exceeded US$ 70 Billion for the
1st time as Europe and Canada also enjoyed double digit growth. Venture
funding throughout the world reached a record US$ 5.4 Billion, also
total financing registered a growth of 42% to reach US $27.9 Billion.
Value of biotechnology market globally is expected to be US$ 226.1
Billion by the year 2010.
According to RNCOS report "US Biotech Market Analysis", "In 2005, total
revenues generated by the US biotechnology market reached US$ 68.6
Billion, representing a CAGR of 15.16% (between 2001 and 2005). However
the industry is expected to generate US$ 131.8 Billion in revenues
towards the end of 2010."
This research report on "US Biotech Market Analysis" provides extensive
research and objective analysis of the Biotechnology industry in US.
This report helps clients in analyzing the opportunities critical to the
growth of The Biotechnology industry in US. Key issues addressed are:
major market trends in the US Biotechnology industry, opportunities and
challenges before the Biotechnology industry, etc.
Would you like to see your news and articles here? GO>>
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.com®, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.com® or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.com® endorsing the content as a recommendation to buy or sell stock.
|
